The Board of Directors at Poly Medicure has approved the unaudited financial results for the second quarter and first half of fiscal year 2026, ended September 30, 2025. The meeting, which commenced at 12:00 Noon and concluded at 01:40 PM, saw the approval of both consolidated and standalone financial results. Further details on financial performance are outlined in the detailed report.
Financial Performance Highlights
Poly Medicure Limited has announced its unaudited financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2026, ending September 30, 2025. Key figures from the standalone results include:
- Revenue from operations: ₹41,654.17 lacs for Q2 and ₹80,058.84 lacs for H1.
- Total Income: ₹45,026.27 lacs for Q2 and ₹87,583.20 lacs for H1.
- Profit after tax: ₹8,905.05 lacs for Q2 and ₹17,697.94 lacs for H1.
Consolidated Financial Overview
The consolidated financial results provide an overview of the group’s performance, with key highlights including:
- Revenue from operations: ₹44,388.16 lacs for Q2 and ₹84,709.23 lacs for H1.
- Total Income: ₹47,782.59 lacs for Q2 and ₹92,315.46 lacs for H1.
- Profit after tax: ₹9,179.75 lacs for Q2 and ₹18,488.01 lacs for H1.
Key Financial Ratios and Metrics
Several financial ratios and metrics were also reported as part of the financial results, including Basic and Diluted Earnings Per Share (EPS). The basic EPS stood at ₹8.79 for the quarter and ₹17.47 for the half year. The diluted EPS stood at ₹8.78 for the quarter and ₹17.45 for the half year.
Subsidiary & Associate Performance
The consolidated results include the performance of Poly Medicure’s subsidiaries and associates, providing a comprehensive view of the group’s financial health and operational effectiveness. These results include share of profit of an associate and the entities considered for consolidation are listed in Annexure E.
Source: BSE
